Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide

Kit Man Chai, Chih Yen Wang, Hung Jiun Liaw, Kuan Min Fang, Chung Shi Yang, Shun Fen Tzeng

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

We previously found that BRCA1-BRCA2-containing complex subunit 3 (BRCC3) was highly expressed in tumorigenic rat glioma cells. However, the functional role of BRCC3 in human glioma cells remains to be characterized. This study indicated that the upregulation of BRCC3 expression was induced in two human malignant glioblastoma U251 and A172 cell lines following exposure to the alkylating agent, temozolomide (TMZ). Homologous recombination (HR)-dependent DNA repair-associated genes (i.e. BRCA1, BRCA2, RAD51 and FANCD2) were also increased in U251 and A172 cells after treatment with TMZ. BRCC3 gene knockdown through lentivirus-mediated gene knockdown approach not only significantly reduced the clonogenic and migratory abilities of U251 and A172 cells, but also enhanced their sensitization to TMZ. The increase in phosphorylated H2AX foci (γH2AX) formation, an indicator of DNA damage, persisted in TMZ-treated glioma cells with stable knockdown BRCC3 expression, suggesting that BRCC3 gene deficiency is associated with DNA repair impairment. In summary, we demonstrate that by inducing DNA repair, BRCC3 renders glioma cells resistant to TMZ. The findings point to BRCC3 as a potential target for treatment of alkylating drug-resistant glioma.

Original languageEnglish
Pages (from-to)10901-10915
Number of pages15
JournalOncotarget
Volume5
Issue number21
DOIs
Publication statusPublished - 2014

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide'. Together they form a unique fingerprint.

Cite this